Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Tuberculosis

Free Subscription Articles published in Int J Tuberc Lung Dis Retrieve available abstracts of 337 articles: HTML format

Single Articles

November 2021
1. ANTONY S, Bodhanwala M, Shah I
   Clinical profile and outcomes of paediatric central nervous system tuberculomas.
   Int J Tuberc Lung Dis. 2021;25:953-955.
   PubMed    
   
   
   
2. FUKUSHIMA K, Akagi K, Kondoh A, Kubo T, et al
   Evaluation of QFT-Plus performance using blood samples stored at room temperature.
   Int J Tuberc Lung Dis. 2021;25:948-949.
   PubMed    
   
   
   
3. WOLTERS BA, Aartsma Y, Jansen K, van Hest R, et al
   Travel history and challenges of screening for latent TB infection in child asylum seekers.
   Int J Tuberc Lung Dis. 2021;25:945-947.
   PubMed    
   
   
   
4. CHRISTOPHER DJ, Coelho V, Ebby GS, Shankar D, et al
   Incremental yield of Xpert((R)) MTB/RIF Ultra over Xpert((R)) MTB/RIF in the diagnosis of extrapulmonary TB.
   Int J Tuberc Lung Dis. 2021;25:939-944.
   PubMed     Abstract available
   
   
   
5. GATECHOMPOL S, Sophonphan J, Kerr SJ, Ubolyam S, et al
   Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV.
   Int J Tuberc Lung Dis. 2021;25:933-938.
   PubMed     Abstract available
   
   
   
6. KASWA M, Minga G, Nkiere N, Mingiedi B, et al
   The economic burden of TB-affected households in DR Congo.
   Int J Tuberc Lung Dis. 2021;25:923-932.
   PubMed     Abstract available
   
   
   
7. STIEBER F, Howard J, Manissero D, Boyle J, et al
   Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis.
   Int J Tuberc Lung Dis. 2021;25:917-922.
   PubMed     Abstract available
   
   
   
8. MURITHI W, Click ES, McCarthy KD, Okeyo E, et al
   Need for caution when interpreting Xpert((R)) MTB/RIF results for rifampin resistance among children.
   Int J Tuberc Lung Dis. 2021;25:911-916.
   PubMed     Abstract available
   
   
   
9. LUAN L, Fraisse P, Cordel H, Charlois C, et al
   Screening for active and latent TB among migrants in France.
   Int J Tuberc Lung Dis. 2021;25:903-910.
   PubMed     Abstract available
   
   
   
10. WINCKLER JL, Schaaf HS, Draper HR, McIlleron H, et al
    Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:896-902.
    PubMed     Abstract available
    
    
    
11. TAAFFE J, Croda J, Moultrie H, Silva DS, et al
    Advancing TB research using digitized programmatic data.
    Int J Tuberc Lung Dis. 2021;25:890-895.
    PubMed     Abstract available
    
    
    
12. BOEREE MJ, Lange C, Thwaites G, Paton N, et al
    UNITE4TB: a new consortium for clinical drug and regimen development for TB.
    Int J Tuberc Lung Dis. 2021;25:886-889.
    PubMed    
    
    
    
13. OCHERETINA O, Brandao AP, Pang Y, Rodrigues C, et al
    Impact of the bacillary load on the accuracy of rifampicin resistance results by Xpert((R)) MTB/RIF.
    Int J Tuberc Lung Dis. 2021;25:881-885.
    PubMed    
    
    
    
14. ALFFENAAR JC, Marais BJ, Thomas TA
    Is a high dose sufficient to achieve high isoniazid exposure in children affected by multidrug-resistant TB?
    Int J Tuberc Lung Dis. 2021;25:879-880.
    PubMed    
    
    
    October 2021
15. SEKANDI JN, Tucker EG, Zalwango S, Buregyeya E, et al
    Digital technologies and loss to follow-up for TB patients.
    Int J Tuberc Lung Dis. 2021;25:871-872.
    PubMed    
    
    
    
16. HASSAN L, Ali SM, Iqbal W, Baig S, et al
    Automated detection and reduction of stigma in online discussions about TB.
    Int J Tuberc Lung Dis. 2021;25:869-870.
    PubMed    
    
    
    
17. ARENAS-MIRAS M, Sanchez-Martinez F, Jove-Caballe N, Villar-Garcia J, et al
    Clinical experience of TB in patients treated with anti-TNF-alpha.
    Int J Tuberc Lung Dis. 2021;25:866-868.
    PubMed    
    
    
    
18. TAHSEEN S, Khanzada FM, Hussain A, Akhtar N, et al
    Phenotypic vs. genotypic resistance to fluoroquinolones in rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:861-863.
    PubMed    
    
    
    
19. EJO M, Van Deun A, Nunn A, Meredith S, et al
    Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial.
    Int J Tuberc Lung Dis. 2021;25:839-845.
    PubMed     Abstract available
    
    
    
20. BLACK M, Da Silva P, Scott L
    Rifampicin-resistant TB: discordance between Xpert((R)) MTB/RIF and MTBDRplus results.
    Int J Tuberc Lung Dis. 2021;25:832-838.
    PubMed     Abstract available
    
    
    
21. OXLADE O, den Boon S, Menzies D, Falzon D, et al
    TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up.
    Int J Tuberc Lung Dis. 2021;25:823-831.
    PubMed     Abstract available
    
    
    
22. PURCHASE S, Batist E, Mmile N, Nkosi S, et al
    Challenges in recruiting children to a multidrug-resistant TB prevention trial.
    Int J Tuberc Lung Dis. 2021;25:814-822.
    PubMed     Abstract available
    
    
    September 2021
23. KOZINSKA M, Podlasin R, Ropelewska-Lacka K, Wojtycha-Kwasnica B, et al
    TB and COVID-19 coinfection.
    Int J Tuberc Lung Dis. 2021;25:776-777.
    PubMed    
    
    
    
24. MOHR-HOLLAND E, Hacking D, Daniels J, Scott V, et al
    Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19.
    Int J Tuberc Lung Dis. 2021;25:772-775.
    PubMed    
    
    
    
25. GIGANTE AR, Sousa M, Aguiar A, Pinto M, et al
    The impact of COVID-19 on the TB response: data from the field.
    Int J Tuberc Lung Dis. 2021;25:769-771.
    PubMed    
    
    
    August 2021
26. RANAIVOMANANA P, Knoblauch AM, Razafimahatratra MC, Raherinandrasana AH, et al
    Pulmonary and pleural TB prevalence in pregnant women.
    Int J Tuberc Lung Dis. 2021;25:668-670.
    PubMed    
    
    
    
27. EDDY JJ, Seth B, White LF, Sulis CA, et al
    Decreasing time spent in airborne infection isolation during TB testing.
    Int J Tuberc Lung Dis. 2021;25:665-667.
    PubMed    
    
    
    
28. CLARKSON MC, McQuaid CF, Houben RM, Kranzer K, et al
    Better data for country-level TB resource allocation are urgently required.
    Int J Tuberc Lung Dis. 2021;25:662-664.
    PubMed    
    
    
    
29. PERRY A, Chitnis A, Chin A, Hoffmann C, et al
    Real-world implementation of video-observed therapy in an urban TB program in the United States.
    Int J Tuberc Lung Dis. 2021;25:655-661.
    PubMed     Abstract available
    
    
    
30. SMITH AGC, Gujabidze M, Avaliani T, Blumberg HM, et al
    Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens.
    Int J Tuberc Lung Dis. 2021;25:632-639.
    PubMed     Abstract available
    
    
    
31. SHARMA K, Sharma M, Modi M, Singla N, et al
    Comparative analysis of Truenat MTB Plus and Xpert((R)) Ultra in diagnosing tuberculous meningitis.
    Int J Tuberc Lung Dis. 2021;25:626-631.
    PubMed     Abstract available
    
    
    
32. CAMPBELL JR, Katamba A, Oxlade O, Schwartzman K, et al
    Improving country-level modelling to support TB prevention and care.
    Int J Tuberc Lung Dis. 2021;25:607-608.
    PubMed    
    
    
    
33. DONOVAN J, Walker TM
    Diagnosing tuberculous meningitis: a testing process.
    Int J Tuberc Lung Dis. 2021;25:605-606.
    PubMed    
    
    
    July 2021
34. AMOUR M, von Reyn CF
    A new paradigm: testing household contacts of adolescents with incident TB infection.
    Int J Tuberc Lung Dis. 2021;25:599b-600.
    PubMed    
    
    
    
35. RODRIGUEZ CA, Brooks MB, Aibana O, Mitnick CD, et al
    Sputum culture conversion definitions and analytic practices for multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:596-598.
    PubMed    
    
    
    
36. ERISA KC, Robsky KO, Kitonsa PJ, Nalutaaya A, et al
    Low prevalence of diabetes mellitus in TB patients and the community in urban Uganda.
    Int J Tuberc Lung Dis. 2021;25:590-592.
    PubMed    
    
    
    
37. DOUGLAS-JONES B, Mohr-Holland E, Mema N, Mathee S, et al
    A home-based care programme for rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:587-589.
    PubMed    
    
    
    
38. HABIB SS, Malik AA, Khan U, Khowaja S, et al
    Impact of upfront Xpert testing on time to treatment initiation for multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:584-586.
    PubMed    
    
    
    
39. MORAN A, Lebona L, Makgopa G, Nkwane Y, et al
    One size does not fit all: reaching agricultural workers in South Africa with TB services.
    Int J Tuberc Lung Dis. 2021;25:573-578.
    PubMed     Abstract available
    
    
    
40. YANGTHARA B, Wutthigate P, Roongmaitree S, Siripattanapipong P, et al
    Nosocomial TB in two neonatal intensive care units at a tertiary care centre: infection risk and outcomes.
    Int J Tuberc Lung Dis. 2021;25:567-572.
    PubMed     Abstract available
    
    
    
41. BLACK DA, McBrien SW, Gersh J, Ghassemieh B, et al
    TB risk by time since U.S. entry among non-U.S.-born residents of Washington State, USA.
    Int J Tuberc Lung Dis. 2021;25:560-566.
    PubMed     Abstract available
    
    
    
42. FEUTH T, Patovirta RL, Grierson S, Danilovits M, et al
    Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines.
    Int J Tuberc Lung Dis. 2021;25:554-559.
    PubMed     Abstract available
    
    
    
43. LARGEN A, Ayala A, Khurana R, Katz DJ, et al
    Evaluation of point-of-care algorithms to detect diabetes during screening for latent TB infection.
    Int J Tuberc Lung Dis. 2021;25:547-553.
    PubMed     Abstract available
    
    
    
44. BALUKU JB, Nuwagira E, Bongomin F, Denning DW, et al
    Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities.
    Int J Tuberc Lung Dis. 2021;25:537-546.
    PubMed     Abstract available
    
    
    
45. SHARMA M, Onozaki I, Nunn P
    TB in older people in Asia: why it is important.
    Int J Tuberc Lung Dis. 2021;25:521-524.
    PubMed    
    
    
    
46. SALZER HJF, Wang JY
    Chronic pulmonary aspergillosis as a sequel to pulmonary TB.
    Int J Tuberc Lung Dis. 2021;25:519-520.
    PubMed    
    
    
    June 2021
47. AGOSTINIS A, Heffernan C, Long R, Beckon A, et al
    Interferon-gamma release assays for latent tuberculosis infection screening in Canadian federal correctional facilities.
    Int J Tuberc Lung Dis. 2021;25:447-452.
    PubMed     Abstract available
    
    
    
48. TEO AKJ, Ong CWM, Hsu LY
    COVID-19 and TB: a progression-regression conundrum.
    Int J Tuberc Lung Dis. 2021;25:421-423.
    PubMed    
    
    
    
49. BASHAM CA, Romanowski K, Johnston JC
    Alcohol use disorder and TB survivor health.
    Int J Tuberc Lung Dis. 2021;25:516-517.
    PubMed    
    
    
    
50. MANTSHONYANE L, Kgwaadira B, Gross R
    The absence of evidence of cure is not a risk for recurrent TB among patients treated for TB.
    Int J Tuberc Lung Dis. 2021;25:511-512.
    PubMed    
    
    
    
51. ROYCROFT E, Fitzgibbon MM, Kelly DM, Scully M, et al
    The largest prison outbreak of TB in Western Europe investigated using whole-genome sequencing.
    Int J Tuberc Lung Dis. 2021;25:491-497.
    PubMed     Abstract available
    
    
    
52. SZKWARKO D, Amisi JA, Peterson D, Burudi S, et al
    Using a mobile application to improve pediatric presumptive TB identification in western Kenya.
    Int J Tuberc Lung Dis. 2021;25:468-474.
    PubMed     Abstract available
    
    
    
53. REDWOOD L, Mitchell EMH, Viney K, Snow K, et al
    Depression, stigma and quality of life in people with drug-susceptible TB and drug-resistant TB in Vietnam.
    Int J Tuberc Lung Dis. 2021;25:461-467.
    PubMed     Abstract available
    
    
    
54. OELOFSE S, Esmail A, Diacon AH, Conradie F, et al
    Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
    Int J Tuberc Lung Dis. 2021;25:453-460.
    PubMed     Abstract available
    
    
    
55. CHAISSON LH, Naufal F, Delgado-Barroso P, Alvarez-Manzo HS, et al
    A systematic review of the number needed to screen for active TB among people living with HIV.
    Int J Tuberc Lung Dis. 2021;25:427-435.
    PubMed     Abstract available
    
    
    
56. TAVOSCHI L, Toscanini F, Pontali E
    TB and prisons: confinement does not contain the disease.
    Int J Tuberc Lung Dis. 2021;25:424-426.
    PubMed    
    
    
    
57. AKKERMAN OW, Tiberi S, Alffenaar JW
    Shortening MDR-TB treatment: is treating more patients with fewer drugs better?
    Int J Tuberc Lung Dis. 2021;25:419-420.
    PubMed    
    
    
    May 2021
58. ZOKUFA N, Lebelo K, Hacking D, Tabo L, et al
    Community-based TB testing as an essential part of TB recovery plans in the COVID-19 era.
    Int J Tuberc Lung Dis. 2021;25:406-408.
    PubMed    
    
    
    
59. POLLOCK NR, MacIntyre AT, Blauwkamp TA, Blair L, et al
    Detection of Mycobacterium tuberculosis cell-free DNA to diagnose TB in pediatric and adult patients.
    Int J Tuberc Lung Dis. 2021;25:403-405.
    PubMed    
    
    
    
60. MIN J, Kang JY, Kim J, Yang J, et al
    Impact of COVID-19 on TB services in Korea.
    Int J Tuberc Lung Dis. 2021;25:400-402.
    PubMed    
    
    
    
61. MARGINEANU I, Mor Z, Garcia D, Gilpin C, et al
    TB and COVID-19 in migrants - the need to focus on both conditions.
    Int J Tuberc Lung Dis. 2021;25:333-335.
    PubMed    
    
    
    
62. MCQUAID CF, Foster N, Quaife M, Levy J, et al
    Digital adherence technology for TB: focus on livelihoods as well as lives.
    Int J Tuberc Lung Dis. 2021;25:416-417.
    PubMed    
    
    
    
63. RICCARDI N, Saderi L, Borroni E, Tagliani E, et al
    Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.
    Int J Tuberc Lung Dis. 2021;25:395-399.
    PubMed     Abstract available
    
    
    
64. KALEMA N, Semeere A, Banturaki G, Kyamugabwa A, et al
    Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: an explanatory sequential cascade analysis.
    Int J Tuberc Lung Dis. 2021;25:388-394.
    PubMed     Abstract available
    
    
    
65. SATYANARAYANA S, Bhatia V, Mandal PP, Kanchar A, et al
    Urgent need to address the slow scale-up of TB preventive treatment in the WHO South-East Asia Region.
    Int J Tuberc Lung Dis. 2021;25:382-387.
    PubMed     Abstract available
    
    
    
66. FERREIRO L, Ruano-Ravina A, Otero-Mallo R, Pou-Alvarez C, et al
    Recent epidemiological trends in extrapulmonary TB in Galicia, Spain.
    Int J Tuberc Lung Dis. 2021;25:373-381.
    PubMed     Abstract available
    
    
    
67. WEYENGA H, Karanja M, Onyango E, Katana AK, et al
    Can isoniazid preventive therapy be scaled up rapidly? Lessons learned in Kenya, 2014-2018.
    Int J Tuberc Lung Dis. 2021;25:367-372.
    PubMed     Abstract available
    
    
    
68. MARTSON AG, Kim HY, Marais B, Alffenaar JW, et al
    The importance of pharmacokinetics/pharmacodynamics assessment in Phase IIB/III trials for MDR-TB treatment.
    Int J Tuberc Lung Dis. 2021;25:336-339.
    PubMed    
    
    
    April 2021
69. MALABAD JCM, Ang CF, Palabrica FAR, Cajucom MAM, et al
    Molecular epidemiology of Mycobacterium tuberculosis in adult Filipino TB-HIV co-infected patients.
    Int J Tuberc Lung Dis. 2021;25:285-291.
    PubMed     Abstract available
    
    
    
70. HARRIES AD, Kumar AMV, Satyanarayana S, Thekkur P, et al
    TB and COVID-19: measuring key risk factors that affect treatment outcomes.
    Int J Tuberc Lung Dis. 2021;25:329-331.
    PubMed    
    
    
    
71. COX V, Guglielmetti L, Hewison C, Reuter A, et al
    Reply to: "Human rights: finding the right balance for rifampicin-resistant TB treatment".
    Int J Tuberc Lung Dis. 2021;25:328-329.
    PubMed    
    
    
    
72. VAN DEUN A, Piubello A, Lynen L, de Jong BC, et al
    Human rights: finding the right balance for rifampicin-resistant TB treatment.
    Int J Tuberc Lung Dis. 2021;25:327-328.
    PubMed    
    
    
    
73. GULLON-BLANCO JA, Rodrigo-Sanz T, Alvarez-Navascues F, Tabernero-Huguet E, et al
    Completion of treatment for latent TB infection in a low prevalence setting.
    Int J Tuberc Lung Dis. 2021;25:321-323.
    PubMed    
    
    
    
74. ROY N, Krishnamoorthy Y, Rajaa S, Ezhumalai K, et al
    Health-related quality of life and its effect on TB treatment outcomes.
    Int J Tuberc Lung Dis. 2021;25:318-320.
    PubMed    
    
    
    
75. BHERING M, Duarte R, Kritski A
    Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil.
    Int J Tuberc Lung Dis. 2021;25:292-298.
    PubMed     Abstract available
    
    
    
76. CHESOV D, Butov D, Reimann M, Heyckendorf J, et al
    Impact of lung function on treatment outcome in patients with TB.
    Int J Tuberc Lung Dis. 2021;25:277-284.
    PubMed     Abstract available
    
    
    
77. VISCA D, D Ambrosio L, Centis R, Pontali E, et al
    Post-TB disease: a new topic for investigation-and why it matters.
    Int J Tuberc Lung Dis. 2021;25:258-261.
    PubMed    
    
    
    
78. LAU A, Ferrara G
    Disseminated TB: still being missed and misunderstood.
    Int J Tuberc Lung Dis. 2021;25:255-257.
    PubMed    
    
    
    
79. SCHULTINK MP, Kerstjens HAM, Ter Beek L, Zondag H, et al
    Assessment of TB treatment on patient well-being.
    Int J Tuberc Lung Dis. 2021;25:315-317.
    PubMed    
    
    
    March 2021
80. KUMAR MS, Surendran D, Manu MS, Rakesh PS, et al
    Mortality due to TB-COVID-19 coinfection in India.
    Int J Tuberc Lung Dis. 2021;25:250-251.
    PubMed    
    
    
    
81. GRACIAA DS, Kempker RR, Sanikidze E, Tukvadze S, et al
    TB research amidst the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2021;25:167-170.
    PubMed    
    
    
    
82. ALLWOOD BW, van der Zalm MM, Mortimer K
    Reply to "Clinical care for patients with post TB lung disease".
    Int J Tuberc Lung Dis. 2021;25:253-254.
    PubMed    
    
    
    
83. GUNTHER G, Ithete S
    Clinical care for patients with post-TB lung disease.
    Int J Tuberc Lung Dis. 2021;25:252-253.
    PubMed    
    
    
    
84. PARK JH, Jung J, Kim JY, Hong MJ, et al
    Airborne precautions based on Xpert((R)) MTB/RIF results for patients with presumptive TB.
    Int J Tuberc Lung Dis. 2021;25:244-246.
    PubMed    
    
    
    
85. KIZNY GORDON A, Tong SYC, Martinez E, Crighton T, et al
    TB genomic surveillance and data sharing in recognising contamination events.
    Int J Tuberc Lung Dis. 2021;25:241-243.
    PubMed    
    
    
    
86. BAIK Y, Nalutaaya A, Kitonsa PJ, Dowdy DW, et al
    Infection status of contacts is not associated with severity of TB in the index case.
    Int J Tuberc Lung Dis. 2021;25:237-240.
    PubMed    
    
    
    
87. ADANKWAH E, Arthur RA, Minadzi D, Owusu DO, et al
    Immune response against TB and non-tuberculous mycobacterial pulmonary disease.
    Int J Tuberc Lung Dis. 2021;25:234-236.
    PubMed    
    
    
    
88. MALIK AA, Fuad J, Abbass W, Ikhlaque S, et al
    Preventive treatment of drug-resistant TB in a rural setting.
    Int J Tuberc Lung Dis. 2021;25:231-233.
    PubMed    
    
    
    
89. CATES L, Crudu V, Codreanu A, Ciobanu N, et al
    Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting.
    Int J Tuberc Lung Dis. 2021;25:228-230.
    PubMed    
    
    
    
90. COX SR, Gupte AN, Thomas B, Gaikwad S, et al
    Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men.
    Int J Tuberc Lung Dis. 2021;25:182-190.
    PubMed     Abstract available
    
    
    
91. SOHN H, Sweeney S, Mudzengi D, Creswell J, et al
    Determining the value of TB active case-finding: current evidence and methodological considerations.
    Int J Tuberc Lung Dis. 2021;25:171-181.
    PubMed     Abstract available
    
    
    February 2021
92. BARRETT J, Painter H, Rajgopal A, Keane D, et al
    Increase in disseminated TB during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2021;25:160-166.
    PubMed    
    
    
    
93. ALLWOOD BW, van der Zalm MM, Mortimer K
    Reply to: Taking action to improve post-TB lung health.
    Int J Tuberc Lung Dis. 2021;25:163a-163.
    PubMed    
    
    
    
94. HARRIES AD, Dlodlo RA, Brigden G, Chakaya JM, et al
    Taking action to improve post-TB lung health.
    Int J Tuberc Lung Dis. 2021;25:161-162.
    PubMed    
    
    
    
95. MOLINA-MOYA B, Guglielmetti L, Bothamley G, van Leth F, et al
    Use and impact of molecular methods for detecting drug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:157-159.
    PubMed    
    
    
    
96. LAW WS, Chan CKA, Leung CC
    Management of latent TB infection in child household contacts aged under 5 years.
    Int J Tuberc Lung Dis. 2021;25:151-153.
    PubMed    
    
    
    
97. MEHTA SN, Murrill M, Suryavanshi N, Bhosale R, et al
    TB-related knowledge and stigma among pregnant women in low-resource settings.
    Int J Tuberc Lung Dis. 2021;25:148-150.
    PubMed    
    
    
    
98. ARSCOTT-MILLS T, Ejelonu A, Mokalane K, Machao G, et al
    One third of child TB cases were missing from the national TB register in Botswana.
    Int J Tuberc Lung Dis. 2021;25:142-144.
    PubMed    
    
    
    
99. DE VOS E, Scott L, Voss De Lima Y, Warren RM, et al
    Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.
    Int J Tuberc Lung Dis. 2021;25:134-141.
    PubMed     Abstract available
    
    
    
100. SOTGIU G, Rosales-Klintz S, Centis R, D'Ambrosio L, et al
     TB management in the European Union/European Economic Area: a multi-centre survey.
     Int J Tuberc Lung Dis. 2021;25:126-133.
     PubMed     Abstract available
     
     
     
101. FOX GJ, Johnston JC, Nguyen TA, Majumdar SS, et al
     Active case-finding in contacts of people with TB.
     Int J Tuberc Lung Dis. 2021;25:95-105.
     PubMed     Abstract available
     
     
     
102. LINH NN, Miller C, Marks GB
     Potential benefits of active case finding to reduce the burden of TB.
     Int J Tuberc Lung Dis. 2021;25:93-94.
     PubMed    
     
     
     January 2021
103. SHEN X, Sha W, Yang C, Pan Q, et al
     Continuity of TB services during the COVID-19 pandemic in China.
     Int J Tuberc Lung Dis. 2021;25:81-83.
     PubMed    
     
     
     
104. 
     TB and COVID-19 co-infection: rationale and aims of a global study.
     Int J Tuberc Lung Dis. 2021;25:78-80.
     PubMed    
     
     
     
105. MAUG AKJ, Hossain MA, Gumusboga M, Decroo T, et al
     Finding the right balance between efficacy and tolerability for TB treatment: the search continues.
     Int J Tuberc Lung Dis. 2021;25:84-86.
     PubMed    
     
     
     
106. PARIGI S, Venturini E, Galli L, Chiappini E, et al
     Xpert((R)) MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates.
     Int J Tuberc Lung Dis. 2021;25:75-77.
     PubMed    
     
     
     
107. SAKR CJ, Musharrafieh UM, Banna HS, Hoteit RA, et al
     Risks and benefits of QuantiFERON((R))-TB testing for LTBI screening of health workers.
     Int J Tuberc Lung Dis. 2021;25:72-74.
     PubMed    
     
     
     
108. GENDERINI FG, Dauby N, Delforge M, De Wit S, et al
     TB in the intensive care unit in a low-endemic country.
     Int J Tuberc Lung Dis. 2021;25:69-71.
     PubMed    
     
     
     
109. NABISERE R, Arinaitwe A, Muyise R, Asienzo J, et al
     Implementation of TB preventive therapy in Uganda: effect of an intervention on completion rates.
     Int J Tuberc Lung Dis. 2021;25:64-65.
     PubMed    
     
     
     
110. TUCKER A, Oyuku D, Nalugwa T, Nantale M, et al
     Costs along the TB diagnostic pathway in Uganda.
     Int J Tuberc Lung Dis. 2021;25:61-63.
     PubMed    
     
     
     
111. MAVE V, Kadam D, Gaikwad S, Kinikar A, et al
     Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomes.
     Int J Tuberc Lung Dis. 2021;25:52-60.
     PubMed     Abstract available
     
     
     
112. MESFIN AB, Araia ZZ, Beyene HN, Mebrahtu AH, et al
     First molecular-based anti-TB drug resistance survey in Eritrea.
     Int J Tuberc Lung Dis. 2021;25:43-51.
     PubMed     Abstract available
     
     
     
113. SENEADZA NAH, Antwi S, Yang H, Enimil A, et al
     Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children.
     Int J Tuberc Lung Dis. 2021;25:36-42.
     PubMed     Abstract available
     
     
     
114. WROHAN I, Redwood L, Ho J, Velen K, et al
     Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
     Int J Tuberc Lung Dis. 2021;25:23-30.
     PubMed     Abstract available
     
     
     
115. SOH AZ, Tan CTY, Mok E, Chee CBE, et al
     Adipokines and the risk of active TB: a nested case-control study.
     Int J Tuberc Lung Dis. 2021;25:31-35.
     PubMed     Abstract available
     
     
     December 2020
116. ZHANG H, Cao X, Wang D, Xin H, et al
     The acquisition of Mycobacterium tuberculosis infection in village doctors in China: a prospective study.
     Int J Tuberc Lung Dis. 2020;24:1241-1246.
     PubMed     Abstract available
     
     
     
117. FANG JL, Chao CM, Tang HJ
     The impact of COVID-19 on the diagnosis of TB in Taiwan.
     Int J Tuberc Lung Dis. 2020;24:1321-1322.
     PubMed    
     
     
     
118. SINGH J, Ehtesham NZ, Hasnain SE
     Two parallel pandemics: the challenges faced by countries with COVID-19 and TB.
     Int J Tuberc Lung Dis. 2020;24:1319-1320.
     PubMed    
     
     
     November 2020
119. FATIMA R, Yaqoob A
     In Reply: How TB and COVID-19 compare: an opportunity to integrate both control programmes.
     Int J Tuberc Lung Dis. 2020;24:1227-1228.
     PubMed    
     
     
     
120. DE SOUZA CDF, Coutinho HS, Costa MM, Magalhaes MAFM, et al
     Impact of COVID-19 on TB diagnosis in Northeastern Brazil.
     Int J Tuberc Lung Dis. 2020;24:1220-1222.
     PubMed    
     
     
     
121. ZHOU S, Van Staden Q, Toska E
     Resource reprioritisation amid competing health risks for TB and COVID-19.
     Int J Tuberc Lung Dis. 2020;24:1215-1216.
     PubMed    
     
     
     
122. KADOTA JL, Reza TF, Nalugwa T, Kityamuwesi A, et al
     Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic.
     Int J Tuberc Lung Dis. 2020;24:1212-1214.
     PubMed    
     
     
     
123. HAAS MK, Ignatius EH, Stout JE, Dooley KE, et al
     Finding the right balance between efficacy and tolerability for TB treatment.
     Int J Tuberc Lung Dis. 2020;24:1225b-1226.
     PubMed    
     
     
     
124. WANG EY, Ahluwalia IB, Mase SR
     Response to Correspondence: The impact of smoking on TB treatment outcomes includes recurrent TB.
     Int J Tuberc Lung Dis. 2020;24:1225a-1225.
     PubMed    
     
     
     
125. DHAMGAYE TM
     In reply: Latent TB treatment in pregnant women: a patient perspective.
     Int J Tuberc Lung Dis. 2020;24:1226-1227.
     PubMed    
     
     
     
126. CHIANG CY, Bam TS
     The impact of smoking on TB treatment outcomes includes recurrent TB.
     Int J Tuberc Lung Dis. 2020;24:1224-1225.
     PubMed    
     
     
     October 2020
127. KIM HW, Min J, Shin AY, Koo HK, et al
     Reasons why patients with tuberculosis in South Korea stop anti-TB treatment: a cross-sectional study.
     Int J Tuberc Lung Dis. 2020;24:1016-1023.
     PubMed     Abstract available
     
     
     
128. SHAHRIARIRAD R, Fallahi MJ
     TB and the COVID-19 pandemic: brothers in arms against lung health.
     Int J Tuberc Lung Dis. 2020;24:1126-1127.
     PubMed    
     
     
     
129. WU Z, Chen J, Xia Z, Pan Q, et al
     Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China.
     Int J Tuberc Lung Dis. 2020;24:1122-1124.
     PubMed    
     
     
     
130. MENEGUIM AC, Rebello L, Das M, Ravi S, et al
     Adapting TB services during the COVID-19 pandemic in Mumbai, India.
     Int J Tuberc Lung Dis. 2020;24:1119-1121.
     PubMed    
     
     
     
131. HELDAL E, Dlodlo RA
     Estimating subnational TB burden-why not strengthen and use routine recording and reporting?
     Int J Tuberc Lung Dis. 2020;24:1125-1127.
     PubMed    
     
     
     
132. AKKERMAN OW, Tiberi S
     The importance of knowing why TB patients stop anti-TB treatment.
     Int J Tuberc Lung Dis. 2020;24:989-990.
     PubMed    
     
     
     September 2020
133. YASSIN M, Grzemska M
     Response to 'The Green Light Committee could contribute to ending tuberculosis .
     Int J Tuberc Lung Dis. 2020;24:984.
     PubMed    
     
     
     
134. NGUYEN TBP, Nguyen TA, Luu BK, Le TTO, et al
     A comparison of digital chest radiography and Xpert((R)) MTB/RIF in active case finding for tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:934-940.
     PubMed     Abstract available
     
     
     
135. CHIANG CH, Lee GH, Chiang TH, Tang PU, et al
     Disseminated Mycobacterium avium complex infection as a differential diagnosis of tuberculosis in HIV patients.
     Int J Tuberc Lung Dis. 2020;24:922-927.
     PubMed     Abstract available
     
     
     
136. LOVEDAY M, Hlangu S, Furin J
     Breastfeeding in women living with tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:880-891.
     PubMed     Abstract available
     
     
     
137. ADEWOLE OO
     Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria.
     Int J Tuberc Lung Dis. 2020;24:981-982.
     PubMed    
     
     
     
138. VAN DER WALT M, Keddy KH
     How COVID-19 can instruct TB research: ensuring the safety of researchers exposed to infectious disease.
     Int J Tuberc Lung Dis. 2020;24:978-980.
     PubMed    
     
     
     
139. WILSON FA, Miller TL, Stimpson JP
     COVID-19 and TB control in immigrant communities.
     Int J Tuberc Lung Dis. 2020;24:975-977.
     PubMed    
     
     
     
140. ECHEVERRIA G, Espinoza W, de Waard JH
     How TB and COVID-19 compare: an opportunity to integrate both control programmes.
     Int J Tuberc Lung Dis. 2020;24:971-974.
     PubMed    
     
     
     
141. MULDER C, Nkiligi E, Kondo Z, Scholten JN, et al
     What to look for when using SUBsET for subnational TB incidence estimates.
     Int J Tuberc Lung Dis. 2020;24:983-984.
     PubMed    
     
     
     
142. WANG J, Garcia-Basteiro AL
     Should vitamin D supplementation be used concomitantly with LTBI treatment?
     Int J Tuberc Lung Dis. 2020;24:875-876.
     PubMed    
     
     
     August 2020
143. KOURA KG, Harries AD, Fujiwara PI, Dlodlo RA, et al
     COVID-19 in Africa: community and digital technologies for tuberculosis management.
     Int J Tuberc Lung Dis. 2020;24:863-865.
     PubMed    
     
     
     
144. LOUIE JK, Reid M, Stella J, Agraz-Lara R, et al
     A decrease in tuberculosis evaluations and diagnoses during the COVID-19 pandemic.
     Int J Tuberc Lung Dis. 2020;24:860-862.
     PubMed    
     
     
     
145. DEWI IMW, Soeroto AY, Putriyani G, Hanifah W, et al
     Aspergillus fumigatus-specific antibodies in patients with chronic tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:853-856.
     PubMed    
     
     
     
146. SILVA LL, Valverde TL, de Carvalho Dutra A, De Andrade L, et al
     Geospatial analysis and factors associated with poor outcome for multidrug-resistant tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:844-846.
     PubMed    
     
     
     
147. ALLWOOD BW, van der Zalm MM, Amaral AFS, Byrne A, et al
     Post-tuberculosis lung health: perspectives from the First International Symposium.
     Int J Tuberc Lung Dis. 2020;24:820-828.
     PubMed     Abstract available
     
     
     
148. CHIMEH RA, Gafar F, Pradipta IS, Akkerman OW, et al
     Clinical and economic impact of medication non-adherence in drug-susceptible tuberculosis: a systematic review.
     Int J Tuberc Lung Dis. 2020;24:811-819.
     PubMed     Abstract available
     
     
     
149. SIAPKA M, Vassall A, Cunnama L, Pineda C, et al
     Cost of tuberculosis treatment in low- and middle-income countries: systematic review and meta-regression.
     Int J Tuberc Lung Dis. 2020;24:802-810.
     PubMed     Abstract available
     
     
     
150. HAN X, Chen X, Sha W, Zhang X, et al
     Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
     Int J Tuberc Lung Dis. 2020;24:789-794.
     PubMed     Abstract available
     
     
     
151. MCARDLE AJ, Keane D, Seddon JA, Bernatoniene J, et al
     Vitamin D deficiency is associated with tuberculosis disease in British children.
     Int J Tuberc Lung Dis. 2020;24:782-788.
     PubMed     Abstract available
     
     
     
152. VISCA D, Centis R, Munoz-Torrico M, Pontali E, et al
     Post-tuberculosis sequelae: the need to look beyond treatment outcome.
     Int J Tuberc Lung Dis. 2020;24:761-762.
     PubMed    
     
     
     
153. ZUMLA A, Marais BJ, McHugh TD, Maeurer M, et al
     COVID-19 and tuberculosis-threats and opportunities.
     Int J Tuberc Lung Dis. 2020;24:757-760.
     PubMed    
     
     
     
154. JAMAL WZ, Habib S, Khowaja S, Safdar N, et al
     COVID-19: ensuring continuity of TB services in the private sector.
     Int J Tuberc Lung Dis. 2020;24:870-872.
     PubMed    
     
     
     
155. WATTS K, McKeown A, Denholm J, Baker AM, et al
     Responding to COVID-19: adjusting TB services in a low-burden setting.
     Int J Tuberc Lung Dis. 2020;24:866-869.
     PubMed    
     
     
     
156. CHIANG CY
     Green Light Committee and WHO recommendations.
     Int J Tuberc Lung Dis. 2020;24:873-874.
     PubMed    
     
     
     July 2020
157. KUBIAK RW, Drain PK, Hochberg NS
     How should body mass index inform active tuberculosis screening in diabetes clinics in Asia?
     Int J Tuberc Lung Dis. 2020;24:753.
     PubMed    
     
     
     
158. LIU C, Yu Y, Fleming J, Wang T, et al
     Severe COVID-19 cases with a history of active or latent tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:747-749.
     PubMed    
     
     
     
159. BURZYNSKI J, Macaraig M, Nilsen D, Schluger NW, et al
     Transforming essential services for tuberculosis during the COVID-19 pandemic: lessons from New York City.
     Int J Tuberc Lung Dis. 2020;24:735-736.
     PubMed    
     
     
     
160. KADOTA JL, Katamba A, Musinguzi A, Welishe F, et al
     Willingness to accept reimbursement for visits to an HIV clinic for tuberculosis preventive therapy.
     Int J Tuberc Lung Dis. 2020;24:729-731.
     PubMed    
     
     
     
161. CHIANG SS, Beckhorn CB, Wong M, Lecca L, et al
     Patterns of suboptimal adherence among adolescents treated for tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:723-725.
     PubMed    
     
     
     
162. VISCA D, Centis R, D'Ambrosio L, Munoz-Torrico M, et al
     The need for pulmonary rehabilitation following tuberculosis treatment.
     Int J Tuberc Lung Dis. 2020;24:720-722.
     PubMed    
     
     
     
163. EDWARDS T, White LV, Lee N, Castro MC, et al
     Effects of comorbidities on quality of life in Filipino people with tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:712-719.
     PubMed     Abstract available
     
     
     
164. IQBAL SA, Isenhour CJ, Mazurek G, Truman BI, et al
     Diagnostic code agreement for electronic health records and claims data for tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:706-711.
     PubMed     Abstract available
     
     
     
165. MUNOZ-TORRICO M, Cid-Juarez S, Gochicoa-Rangel L, Torre-Bouscolet L, et al
     Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:700-705.
     PubMed     Abstract available
     
     
     
166. WATTHANANUKUL T, Liabsuetrakul T, Pungrassami P, Chongsuvivatwong V, et al
     Effect of Global Fund financial support for patients with multidrug-resistant tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:686-693.
     PubMed     Abstract available
     
     
     
167. RICKMAN HM, Cohn S, Lala SG, Waja Z, et al
     Subclinical tuberculosis and adverse infant outcomes in pregnant women with HIV.
     Int J Tuberc Lung Dis. 2020;24:681-685.
     PubMed     Abstract available
     
     
     
168. MADHANI F, Maniar RA, Burfat A, Ahmed M, et al
     Automated chest radiography and mass systematic screening for tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:665-673.
     PubMed     Abstract available
     
     
     
169. BASHAM CA, Grewal N, Orr PH, McMullin K, et al
     What will it take to achieve meaningful action on tuberculosis among Indigenous Peoples?
     Int J Tuberc Lung Dis. 2020;24:661-664.
     PubMed    
     
     
     
170. ROSSATO SILVA D, van den Hof S
     Use of insurance claims and electronic health records to assess tuberculosis and latent tuberculosis diagnosis.
     Int J Tuberc Lung Dis. 2020;24:659-660.
     PubMed    
     
     
     
171. TADYANEMHANDU C, Chirenda J, Garvey C, Metcalfe J, et al
     Treatment success, but living with the consequences of post-tuberculosis sequelae.
     Int J Tuberc Lung Dis. 2020;24:657-658.
     PubMed    
     
     
     
172. SCHAAF HS, du Preez K, Kruger M, Solomons R, et al
     Bacille Calmette-Guerin (BCG) vaccine and the COVID-19 pandemic: responsible stewardship is needed.
     Int J Tuberc Lung Dis. 2020;24:732-734.
     PubMed    
     
     
     June 2020
173. DE SOUZA JVP, Murase LS, Caleffi-Ferracioli KR, Palomo CT, et al
     Isoniazid and verapamil modulatory activity and efflux pump gene expression in Mycobacterium tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:591-596.
     PubMed     Abstract available
     
     
     
174. GUPTA A, Singla R, Caminero JA, Singla N, et al
     Impact of COVID-19 on tuberculosis services in India.
     Int J Tuberc Lung Dis. 2020;24:637-639.
     PubMed    
     
     
     
175. SANDY C, Takarinda KC, Timire C, Mutunzi H, et al
     Preparing national tuberculosis control programmes for COVID-19.
     Int J Tuberc Lung Dis. 2020;24:634-636.
     PubMed    
     
     
     
176. PROOPS DC, Knorr JA, Meissner JS, Kreiswirth BN, et al
     Epidemiology of tuberculosis among healthcare personnel in New York City.
     Int J Tuberc Lung Dis. 2020;24:619-625.
     PubMed     Abstract available
     
     
     
177. COCOZZA AM, Linh NN, Jaramillo E
     Is effective patient support missing in the global response to multidrug-resistant tuberculosis?
     Int J Tuberc Lung Dis. 2020;24:626-630.
     PubMed     Abstract available
     
     
     
178. ONGOLE JJ, Rossouw TM, Fourie PB, Stoltz AC, et al
     Sustaining essential healthcare in Africa during the COVID-19 pandemic.
     Int J Tuberc Lung Dis. 2020;24:643-645.
     PubMed    
     
     
     
179. VAN CREVEL R, Andia-Biraro I, Ntinginya NE, Chamba N, et al
     Response to IJTLD article, "Having diabetes and being underweight in Asia: a potent risk factor for tuberculosis".
     Int J Tuberc Lung Dis. 2020;24:632-633.
     PubMed    
     
     
     
180. NAMKOONG H, Horita N, Ebina-Shibuya R
     Concern over a COVID-19-related BCG shortage.
     Int J Tuberc Lung Dis. 2020;24:642-643.
     PubMed    
     
     
     
181. MORAN A, Kula N, Jagwer G, Broughton E, et al
     Examining the cost of community-based tuberculosis treatment in South Africa.
     Int J Tuberc Lung Dis. 2020;24:612-618.
     PubMed     Abstract available
     
     
     
182. LAZARUS JV
     Correspondence on: "Should we consider a 'fourth 90' for tuberculosis?"
     Int J Tuberc Lung Dis. 2020;24:631-632.
     PubMed    
     
     
     
183. HARRIES AD
     In Response to Reinout van Crevel et al.
     Int J Tuberc Lung Dis. 2020;24:634.
     PubMed    
     
     
     May 2020
184. PANG Y, Liu Y, Du J, Gao J, et al
     Impact of COVID-19 on tuberculosis control in China.
     Int J Tuberc Lung Dis. 2020;24:545-547.
     PubMed    
     
     
     
185. DARA M, Sotgiu G, Reichler MR, Chiang CY, et al
     New diseases and old threats: lessons from tuberculosis for the COVID-19 response.
     Int J Tuberc Lung Dis. 2020;24:544-545.
     PubMed    
     
     
     
186. PONTALI E, Tiberi S
     Green Light Committee and drug-resistant-tuberculosis: how to address the new challenges?
     Int J Tuberc Lung Dis. 2020;24:539.
     PubMed    
     
     
     
187. HENG M, Allmendinger S, Chiang CY, Trebucq A, et al
     Progress in the roll-out of multidrug-resistant tuberculosis (MDR-TB) treatments.
     Int J Tuberc Lung Dis. 2020;24:535-536.
     PubMed    
     
     
     
188. MONDONI M, Sotgiu G
     Endobronchial ultrasound-guided transbronchial needle aspiration and tuberculosis mediastinal lymphadenopathy.
     Int J Tuberc Lung Dis. 2020;24:534.
     PubMed    
     
     
     
189. ARINAMINPATHY N, Chin DP, Sachdeva KS, Rao R, et al
     Modelling the potential impact of adherence technologies on tuberculosis in India.
     Int J Tuberc Lung Dis. 2020;24:526-533.
     PubMed     Abstract available
     
     
     
190. GARFEIN RS, Liu L, Cuevas-Mota J, Collins K, et al
     Evaluation of recorded video-observed therapy for anti-tuberculosis treatment.
     Int J Tuberc Lung Dis. 2020;24:520-525.
     PubMed     Abstract available
     
     
     
191. KAWATSU L, Uchimura K, Ohkado A
     A cost-effectiveness study of tuberculosis and latent tuberculosis infection screening in prisons in Japan.
     Int J Tuberc Lung Dis. 2020;24:506-511.
     PubMed     Abstract available
     
     
     
192. MAUG AKJ, Hossain MA, Gumusboga M, Decroo T, et al
     First-line tuberculosis treatment with double-dose rifampicin is well tolerated.
     Int J Tuberc Lung Dis. 2020;24:499-505.
     PubMed     Abstract available
     
     
     
193. PARK SC, Kang MJ, Han CH, Lee SM, et al
     Long-term mortality of patients with tuberculosis in Korea.
     Int J Tuberc Lung Dis. 2020;24:492-498.
     PubMed     Abstract available
     
     
     
194. BUTOV D, Lange C, Heyckendorf J, Kalmykova I, et al
     Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine.
     Int J Tuberc Lung Dis. 2020;24:485-491.
     PubMed     Abstract available
     
     
     
195. ANDREWS JR, Cobelens F, Horsburgh CR, Hatherill M, et al
     Seasonal drivers of tuberculosis: evidence from over 100 years of notifications in Cape Town.
     Int J Tuberc Lung Dis. 2020;24:477-484.
     PubMed     Abstract available
     
     
     
196. DENHOLM J
     Seasonality, climate change and tuberculosis: new data and old lessons.
     Int J Tuberc Lung Dis. 2020;24:469.
     PubMed    
     
     
     
197. COX V, Wilkinson L, Grimsrud A, Hughes J, et al
     Critical changes to services for TB patients during the COVID-19 pandemic.
     Int J Tuberc Lung Dis. 2020;24:542-544.
     PubMed    
     
     
     
198. ELGER BS, Mirzayev F, Afandiyev S, Gurbanova E, et al
     Ethical issues in tuberculosis screening and the use of new drugs for prisoners.
     Int J Tuberc Lung Dis. 2020;24:57-60.
     PubMed     Abstract available
     
     
     
199. HERMANNS S, Bhan A, Viney K
     Ethics and benefits of systematic screening for active tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:44-47.
     PubMed     Abstract available
     
     
     
200. HUMMEL P, Ahamed N, Amanullah F
     Ethical issues surrounding childhood tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:27-31.
     PubMed     Abstract available
     
     
     
201. DENHOLM JT, Millan-Marcelo JC, Fiekert K
     Latent tuberculosis infection and the EndTB Strategy: ethical tensions and imperatives.
     Int J Tuberc Lung Dis. 2020;24:21-26.
     PubMed     Abstract available
     
     
     
202. BAYER R, Fairchild AL, Zignol M, Castro KG, et al
     Tuberculosis surveillance and its discontents: the ethical paradox.
     Int J Tuberc Lung Dis. 2020;24:9-14.
     PubMed     Abstract available
     
     
     
203. HARDING R, Snyman L, Ostgathe C, Odell S, et al
     The ethical imperative to relieve suffering for people with tuberculosis by ensuring access to palliative care.
     Int J Tuberc Lung Dis. 2020;24:3-8.
     PubMed     Abstract available
     
     
     
204. FURIN J
     Can Green Light Committees help "end TB"?
     Int J Tuberc Lung Dis. 2020;24:540.
     PubMed    
     
     
     April 2020
205. KAPUR A
     Randomised clinical trials for tuberculosis prophylaxis in people with diabetes mellitus.
     Int J Tuberc Lung Dis. 2020;24:465-466.
     PubMed    
     
     
     
206. SHEDRAWY J, Jansson L, Bruchfeld J, Lonnroth K, et al
     Health-related quality of life among persons treated for tuberculosis in a European setting.
     Int J Tuberc Lung Dis. 2020;24:461-463.
     PubMed    
     
     
     
207. SCHWOEBEL V, Koura KG, Adjobimey M, Gnanou S, et al
     Tuberculosis contact investigation and short-course preventive therapy among young children in Africa.
     Int J Tuberc Lung Dis. 2020;24:452-460.
     PubMed     Abstract available
     
     
     
208. YOUNG C, Barker S, Ehrlich R, Kistnasamy B, et al
     Computer-aided detection for tuberculosis and silicosis in chest radiographs of gold miners of South Africa.
     Int J Tuberc Lung Dis. 2020;24:444-451.
     PubMed     Abstract available
     
     
     
209. MIKIASHVILI L, Kipiani M, Schechter MC, Avaliani Z, et al
     Linezolid use for drug-resistant tuberculosis in Georgia: a retrospective cohort study.
     Int J Tuberc Lung Dis. 2020;24:436-443.
     PubMed     Abstract available
     
     
     
210. PIERRE-AUDIGIER C, Talla C, Alame-Emane AK, Audigier B, et al
     Tuberculosis trends in a hot-spot region in Paris, France.
     Int J Tuberc Lung Dis. 2020;24:428-435.
     PubMed     Abstract available
     
     
     
211. TOMENY EM, Mendoza VL, Marcelo DB, Barrameda AJD, et al
     Patient-cost survey for tuberculosis in the context of patient-pathway modelling.
     Int J Tuberc Lung Dis. 2020;24:420-427.
     PubMed     Abstract available
     
     
     
212. O'SON L, Hulland E, Cookson ST, Castro KG, et al
     Epidemiology and risk factors for extrapulmonary tuberculosis in Lebanon.
     Int J Tuberc Lung Dis. 2020;24:414-419.
     PubMed     Abstract available
     
     
     
213. GOBAUD AN, Haley CA, Wilson JW, Bhavaraju R, et al
     Multidrug-resistant tuberculosis care in the United States.
     Int J Tuberc Lung Dis. 2020;24:409-413.
     PubMed     Abstract available
     
     
     
214. MCCREESH N, Grant AD, Yates TA, Karat AS, et al
     Tuberculosis from transmission in clinics in high HIV settings may be far higher than contact data suggest.
     Int J Tuberc Lung Dis. 2020;24:403-408.
     PubMed     Abstract available
     
     
     
215. KIM HY, Hanrahan CF, Dowdy DW, Martinson NA, et al
     Priorities among HIV-positive individuals for tuberculosis preventive therapies.
     Int J Tuberc Lung Dis. 2020;24:396-402.
     PubMed     Abstract available
     
     
     
216. MASUKU SD, Berhanu R, Van Rensburg C, Ndjeka N, et al
     Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis.
     Int J Tuberc Lung Dis. 2020;24:376-382.
     PubMed     Abstract available
     
     
     
217. MILLER CR, Mitchell EMH, Nishikiori N, Zwerling A, et al
     ScreenTB: a tool for prioritising risk groups and selecting algorithms for screening for active tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:367-375.
     PubMed     Abstract available
     
     
     
218. LANEY AS, Pontali E
     Computer-assisted interpretation of chest radiographs: signs of hope for silicosis and tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:362-363.
     PubMed    
     
     
     
219. CRUZ AT, Schwartzman K, Kitai I
     Fighting a hidden epidemic: expanding tuberculosis preventive treatment to the youngest household contacts.
     Int J Tuberc Lung Dis. 2020;24:357-359.
     PubMed    
     
     
     
220. BASHAM CA, Romanowski K, Johnston JC
     Cardiovascular disease: the forgotten cousin of post-TB health?
     Int J Tuberc Lung Dis. 2020;24:466-467.
     PubMed    
     
     
     March 2020
221. HASKER E, Assoumani Y, Mzembaba A, Zakir AM, et al
     Using a geographic information system as a management tool for tuberculosis control.
     Int J Tuberc Lung Dis. 2020;24:354-356.
     PubMed    
     
     
     
222. YATES TA, Tomlinson LA, Douglas IJ
     Proton pump inhibitors and tuberculosis risk.
     Int J Tuberc Lung Dis. 2020;24:353-354.
     PubMed    
     
     
     
223. KOHLENBERG A, Kodmon C, van den Boom M, van der Werf MJ, et al
     Tuberculosis surveillance in adolescents: what to learn from European Union/European Economic Area data?
     Int J Tuberc Lung Dis. 2020;24:347-352.
     PubMed     Abstract available
     
     
     
224. GUNASEKERA K, Cohen T, Gao W, Ayles H, et al
     Smoking and HIV associated with subclinical tuberculosis: analysis of a population-based prevalence survey.
     Int J Tuberc Lung Dis. 2020;24:340-346.
     PubMed     Abstract available
     
     
     
225. NGABONZIZA JS, Habimana YM, Decroo T, Migambi P, et al
     Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda.
     Int J Tuberc Lung Dis. 2020;24:329-339.
     PubMed     Abstract available
     
     
     
226. BONSU F, Addo KK, Alebachew Z, Gyapong J, et al
     National population-based tuberculosis prevalence survey in Ghana, 2013.
     Int J Tuberc Lung Dis. 2020;24:321-328.
     PubMed     Abstract available
     
     
     
227. JANSSON L, Shedrawy J, Lonnroth K, Bruchfeld J, et al
     Latent tuberculosis in pregnant women: a patient perspective.
     Int J Tuberc Lung Dis. 2020;24:310-315.
     PubMed     Abstract available
     
     
     
228. LOPEZ-MEDINA EM, Sainz T, de Ory SJ, Mellado-Pena MJ, et al
     Tuberculosis in a Spanish cohort of children living with HIV: the CHOTIS study (Childhood HIV & TB study).
     Int J Tuberc Lung Dis. 2020;24:303-309.
     PubMed     Abstract available
     
     
     
229. WANG M, Liu F, Li Q, Yin Q, et al
     Quality assessment of guidelines for the management of Mycobacterium tuberculosis infection in children.
     Int J Tuberc Lung Dis. 2020;24:287-294.
     PubMed     Abstract available
     
     
     
230. ARNEDO-PENA A, Juan-Cerdan JV, Romeu-Garcia M, Sorribes-Segura S, et al
     Vitamin D status and latent tuberculosis infection: conversion in nursing homes, Spain.
     Int J Tuberc Lung Dis. 2020;24:278-286.
     PubMed     Abstract available
     
     
     
231. REICHLER MR, Hirsch-Moverman Y
     Antenatal diagnosis of latent tuberculosis infection and post-partum treatment: patient perspectives.
     Int J Tuberc Lung Dis. 2020;24:266-267.
     PubMed    
     
     
     
232. DEDICOAT M
     Where next with for vitamin D and tuberculosis?
     Int J Tuberc Lung Dis. 2020;24:265.
     PubMed    
     
     
     
233. DOWDY DW
     The urgent need to improve clinical practice guidelines for pediatric tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:264.
     PubMed    
     
     
     February 2020
234. SINGH AR, Shewade HD, Pandey R
     Near real-time supervision of home visits for patients with tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:260-261.
     PubMed    
     
     
     
235. TALBOT EA
     Response to Dr Granich's letter regarding 'Tackling drug-resistant tuberculosis: we need a critical synergy of product and process innovations'.
     Int J Tuberc Lung Dis. 2020;24:259.
     PubMed    
     
     
     
236. PARWATI CG, Farid MN, Nasution HS, Basri C, et al
     Estimation of subnational tuberculosis burden: generation and application of a new tool in Indonesia.
     Int J Tuberc Lung Dis. 2020;24:250-257.
     PubMed     Abstract available
     
     
     
237. PARK S, Jo KW, Shim TS
     Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility.
     Int J Tuberc Lung Dis. 2020;24:233-239.
     PubMed     Abstract available
     
     
     
238. QUISPE N, Asencios L, Obregon C, Velasquez GE, et al
     The fourth national anti-tuberculosis drug resistance survey in Peru.
     Int J Tuberc Lung Dis. 2020;24:207-213.
     PubMed     Abstract available
     
     
     
239. GATTI A, Ceriani C, De Paschale M, Magnani C, et al
     Quantification of neutrophil and monocyte CD64 expression: a predictive biomarker for active tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:196-201.
     PubMed     Abstract available
     
     
     
240. WANG EY, Arrazola RA, Mathema B, Ahluwalia IB, et al
     The impact of smoking on tuberculosis treatment outcomes: a meta-analysis.
     Int J Tuberc Lung Dis. 2020;24:170-175.
     PubMed     Abstract available
     
     
     
241. RABKIN M, Howard AA, Ehrenkranz P, Fernandez LG, et al
     Leveraging differentiated HIV service delivery to expand tuberculosis preventive treatment: a call to action.
     Int J Tuberc Lung Dis. 2020;24:165-169.
     PubMed     Abstract available
     
     
     
242. GRANICH R
     Time for hand wringing about TB diagnostics is over: show us the money and the impact.
     Int J Tuberc Lung Dis. 2020;24:258-259.
     PubMed    
     
     
     January 2020
243. WU MY, Shu CC, Lin HH
     Authors reply to letter to the Editor "Chronic kidney disease, tuberculosis and climate change".
     Int J Tuberc Lung Dis. 2020;24:133-134.
     PubMed    
     
     
     
244. HARRIES AD
     Chronic kidney disease, tuberculosis and climate change.
     Int J Tuberc Lung Dis. 2020;24:132-133.
     PubMed    
     
     
     
245. LEROLLE N, Laanani M, Galicier L, Riviere S, et al
     Factors associated with tuberculosis-associated haemophagocytic syndrome: a multicentre case-control study.
     Int J Tuberc Lung Dis. 2020;24:124-130.
     PubMed     Abstract available
     
     
     
246. LINH NN, Wares F, Cocozza AM, Uplekar M, et al
     No universal access to drug-resistant tuberculosis care without engaging all health care providers.
     Int J Tuberc Lung Dis. 2020;24:118-123.
     PubMed     Abstract available
     
     
     
247. DESHMUKH S, Atre S, Chavan A, Raskar S, et al
     Assessment of the Xpert assay among adult pulmonary tuberculosis suspects with and without diabetes mellitus.
     Int J Tuberc Lung Dis. 2020;24:113-117.
     PubMed     Abstract available
     
     
     
248. BARSS L, Moayedi-Nia S, Campbell JR, Oxlade O, et al
     Interventions to reduce losses in the cascade of care for latent tuberculosis: a systematic review and meta-analysis.
     Int J Tuberc Lung Dis. 2020;24:100-109.
     PubMed     Abstract available
     
     
     
249. CHEN MP, Miramontes R, Kammerer JS
     Multidrug-resistant tuberculosis in the United States, 2011-2016: patient characteristics and risk factors.
     Int J Tuberc Lung Dis. 2020;24:92-99.
     PubMed     Abstract available
     
     
     
250. HILL J, Dickson-Hall L, Grant AD, Grundy C, et al
     Drug-resistant tuberculosis patient care journeys in South Africa: a pilot study using routine laboratory data.
     Int J Tuberc Lung Dis. 2020;24:83-91.
     PubMed     Abstract available
     
     
     
251. RAGAN EJ, Kleinman MB, Sweigart B, Gnatienko N, et al
     The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis.
     Int J Tuberc Lung Dis. 2020;24:73-82.
     PubMed     Abstract available
     
     
     
252. HONG H, Dowdy DW, Dooley KE, Francis HW, et al
     Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose.
     Int J Tuberc Lung Dis. 2020;24:65-72.
     PubMed     Abstract available
     
     
     
253. PERUMAL R, Naidoo K, Naidoo A, Ramachandran G, et al
     A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes.
     Int J Tuberc Lung Dis. 2020;24:48-64.
     PubMed     Abstract available
     
     
     
254. COCOZZA AM, Linh NN, Nathavitharana RR, Ahmad U, et al
     An assessment of current tuberculosis patient care and support policies in high-burden countries.
     Int J Tuberc Lung Dis. 2020;24:36-42.
     PubMed     Abstract available
     
     
     
255. REEVES H, Grandjean Lapierre S, Razafindrina K, Andriamiadanarivo A, et al
     Evaluating the use of educational videos to support the tuberculosis care cascade in remote Madagascar.
     Int J Tuberc Lung Dis. 2020;24:28-35.
     PubMed     Abstract available
     
     
     
256. GUTIERREZ C, Somoskovi A
     Serum levels of tuberculosis drugs-beyond the quantitative data.
     Int J Tuberc Lung Dis. 2020;24:6-7.
     PubMed    
     
     
     
257. CHAULK CP, Moonan PK
     Over the limit: tuberculosis and excessive alcohol use.
     Int J Tuberc Lung Dis. 2020;24:3-4.
     PubMed    
     
     
     December 2019
258. DENHOLM JT, Leontiou C, McKeown A, Watts KN, et al
     Speaking up: language services, tuberculosis and human rights.
     Int J Tuberc Lung Dis. 2019;23:1336.
     PubMed    
     
     
     
259. MEKONNEN D, Derbie A, Abeje A, Shumet A, et al
     Genomic diversity and transmission dynamics of M. tuberculosis in Africa: a systematic review and meta-analysis.
     Int J Tuberc Lung Dis. 2019;23:1314-1326.
     PubMed     Abstract available
     
     
     
260. SURIE D, Interrante JD, Pathmanathan I, Patel MR, et al
     Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017.
     Int J Tuberc Lung Dis. 2019;23:1308-1313.
     PubMed     Abstract available
     
     
     
261. LIFAN Z, Sainan B, Feng S, Siyan Z, et al
     Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis.
     Int J Tuberc Lung Dis. 2019;23:1293-1307.
     PubMed     Abstract available
     
     
     
262. HANDEL A, Martinez L, Sekandi JN, Bellan SE, et al
     Evidence for supercoughers in an analysis of six tuberculosis cohorts from China, Peru, The Gambia and Uganda.
     Int J Tuberc Lung Dis. 2019;23:1286-1292.
     PubMed     Abstract available
     
     
     
263. ZMAK L, Obrovac M, Makek MJ, Perko G, et al
     From Peruvian mummies to living humans: first case of pulmonary tuberculosis caused by Mycobacterium pinnipedii.
     Int J Tuberc Lung Dis. 2019;23:1283-1285.
     PubMed     Abstract available
     
     
     
264. SOH AZ, Chee CBE, Wang YT, Yuan JM, et al
     Diabetes and body mass index in relation to risk of active tuberculosis: a prospective population-based cohort.
     Int J Tuberc Lung Dis. 2019;23:1277-1282.
     PubMed     Abstract available
     
     
     
265. PENG Y, Zhu Y, Ao G, Chen Z, et al
     Effect of bronchial artery embolisation on the management of tuberculosis-related haemoptysis.
     Int J Tuberc Lung Dis. 2019;23:1269-1276.
     PubMed     Abstract available
     
     
     
266. WADEMAN DT, Busakwe L, Nicholson TJ, van der Zalm M, et al
     Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial.
     Int J Tuberc Lung Dis. 2019;23:1263-1268.
     PubMed     Abstract available
     
     
     
267. CHANDAK RJ, Malhotra B, Bhargava S, Goel SK, et al
     Evaluation of MTBDRsl for detecting resistance in Mycobacterium tuberculosis to second-line drugs.
     Int J Tuberc Lung Dis. 2019;23:1257-1262.
     PubMed     Abstract available
     
     
     
268. DUNSTAN SJ, Williamson DA, Denholm JT
     Understanding the global tuberculosis epidemic: moving towards routine whole-genome sequencing.
     Int J Tuberc Lung Dis. 2019;23:1241-1242.
     PubMed    
     
     
     
269. HARRIES AD
     Having diabetes and being underweight in Asia: a potent risk factor for tuberculosis.
     Int J Tuberc Lung Dis. 2019;23:1237-1238.
     PubMed    
     
     
     
270. SUDBURY E, Villanueva P, Goetzinger F, Tebruegge M, et al
     The impact of bacille Calmette-Guerin vaccination on tuberculin skin test results in young children.
     Int J Tuberc Lung Dis. 2019;23:1335-1336.
     PubMed    
     
     
     November 2019
271. HARRIES AD, Dlodlo RA, Brigden G, Mortimer K, et al
     Should we consider a 'fourth 90' for tuberculosis?
     Int J Tuberc Lung Dis. 2019 Nov 21. doi: 10.5588/ijtld.19.0471.
     PubMed     Abstract available
     
     
     
272. TIMIRE C, Sandy C, Harries AD
     Eliminating tuberculosis by 2035: tackling the financial barriers at all stages of the cascade of care.
     Int J Tuberc Lung Dis. 2019;23:1235.
     PubMed    
     
     
     
273. COIT J, Mendoza M, Pinedo C, Marin H, et al
     Performance of a household tuberculosis exposure survey among children in a Latin American setting.
     Int J Tuberc Lung Dis. 2019;23:1223-1227.
     PubMed     Abstract available
     
     
     
274. RIVERA VR, Lu L, Ocheretina O, Jean Juste MA, et al
     Diagnostic yield of active case finding for tuberculosis at human immunodeficiency virus testing in Haiti.
     Int J Tuberc Lung Dis. 2019;23:1217-1222.
     PubMed     Abstract available
     
     
     
275. SUMALANI KK, Akhter N, Chawla D, Rizvi NA, et al
     Diagnostic yield of sputum induction in patients with pleural tuberculosis at a tertiary care hospital in Karachi.
     Int J Tuberc Lung Dis. 2019;23:1213-1216.
     PubMed     Abstract available
     
     
     
276. ERLINGER S, Stracker N, Hanrahan C, Nonyane S, et al
     Tuberculosis patients with higher levels of poverty face equal or greater costs of illness.
     Int J Tuberc Lung Dis. 2019;23:1205-1212.
     PubMed     Abstract available
     
     
     
277. JORDAN AM, Podewils LJ, Castro KG, Zishiri V, et al
     Prevalence and risk factors of tuberculosis disease in South African correctional facilities in 2015.
     Int J Tuberc Lung Dis. 2019;23:1198-1204.
     PubMed     Abstract available
     
     
     
278. VINEY K, Amaral S, Marques EB, Siroka A, et al
     Four of five tuberculosis patients experience catastrophic costs related to TB diagnosis and care in Timor-Leste.
     Int J Tuberc Lung Dis. 2019;23:1191-1197.
     PubMed     Abstract available
     
     
     
279. AUGUSTE P, Madan J, Tsertsvadze A, Court R, et al
     Identifying latent tuberculosis in high-risk populations: systematic review and meta-analysis of test accuracy.
     Int J Tuberc Lung Dis. 2019;23:1178-1190.
     PubMed     Abstract available
     
     
     
280. CADMUS S, Akinseye VO, van Soolingen D
     Mycobacterium bovis in humans and M. tuberculosis in animals in Nigeria: an overview from 1975-2014.
     Int J Tuberc Lung Dis. 2019;23:1162-1170.
     PubMed     Abstract available
     
     
     
281. SCHULMAN H, Niward K, Abate E, Idh J, et al
     Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis.
     Int J Tuberc Lung Dis. 2019;23:1155-1161.
     PubMed     Abstract available
     
     
     
282. LAM CK, Fluegge K, Macaraig M, Burzynski J, et al
     Cost savings associated with video directly observed therapy for treatment of tuberculosis.
     Int J Tuberc Lung Dis. 2019;23:1149-1154.
     PubMed     Abstract available
     
     
     
283. BOCCIA D, Bond V
     The catastrophic cost of tuberculosis: advancing research and solutions.
     Int J Tuberc Lung Dis. 2019;23:1129-1130.
     PubMed    
     
     
     
284. SCHON T
     The evaluation of routine immunological tests to estimate the risk of progression into active tuberculosis.
     Int J Tuberc Lung Dis. 2019;23:1127-1128.
     PubMed    
     
     
     
285. PEDRAZZOLI D, Houben R, Viney K, Lonnroth K, et al
     Beyond measurement: taking bold multisector actions towards zero catastrophic costs and suffering due to TB.
     Int J Tuberc Lung Dis. 2019;23:1236.
     PubMed    
     
     
     October 2019
286. FIOGBE AA, Agodokpessi G, Marcy O
     In reply to: Programmatic implementation of screening and management of pulmonary impairment post-tuberculosis in resource-limited countries: challenges and feasibility.
     Int J Tuberc Lung Dis. 2019;23:1123.
     PubMed    
     
     
     
287. OLIVEIRA MCB, Sant'Anna CC, Luiz RR, Soares ECC, et al
     Contribution of Xpert MTB/RIF to clinical diagnosis in adolescents with tuberculosis in Rio de Janeiro, Brazil.
     Int J Tuberc Lung Dis. 2019;23:1115-1121.
     PubMed     Abstract available
     
     
     
288. CAMELIQUE O, Scholtissen S, Dousset JP, Bonnet M, et al
     Mobile community-based active case-finding for tuberculosis among older populations in rural Cambodia.
     Int J Tuberc Lung Dis. 2019;23:1107-1114.
     PubMed     Abstract available
     
     
     
289. VALVI C, Chandanwale A, Khadse S, Kulkarni R, et al
     Delays and barriers to early treatment initiation for childhood tuberculosis in India.
     Int J Tuberc Lung Dis. 2019;23:1090-1099.
     PubMed     Abstract available
     
     
     
290. BHERING M, Kritski A, Nunes C, Duarte R, et al
     Multidrug-resistant tuberculosis in Lisbon: unfavourable treatment and associated factors, 2000-2014.
     Int J Tuberc Lung Dis. 2019;23:1075-1081.
     PubMed     Abstract available
     
     
     
291. COURT R, Chirehwa MT, Wiesner L, de Vries N, et al
     Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis.
     Int J Tuberc Lung Dis. 2019;23:1068-1074.
     PubMed     Abstract available
     
     
     
292. BASTARD M, Sanchez-Padilla E, Hayrapetyan A, Kimenye K, et al
     What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?
     Int J Tuberc Lung Dis. 2019;23:1060-1067.
     PubMed     Abstract available
     
     
     
293. VINEY K, Mills T, Harley D
     Tuberculosis and diabetes mellitus: a dose-response relationship between the odds of tuberculosis and HbA1c.
     Int J Tuberc Lung Dis. 2019;23:1055-1059.
     PubMed     Abstract available
     
     
     
294. GUGLIELMETTI L, Jaffre J, Bernard C, Brossier F, et al
     Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium.
     Int J Tuberc Lung Dis. 2019;23:1050-1054.
     PubMed     Abstract available
     
     
     
295. PONTALI E, Tadolini M, Migliori GB
     TB consilia and quality of tuberculosis management.
     Int J Tuberc Lung Dis. 2019;23:1048-1049.
     PubMed    
     
     
     
296. DOWDY DW
     Implementation of Xpert((R)) MTB/RIF: real challenges, real promise.
     Int J Tuberc Lung Dis. 2019;23:1123.
     PubMed    
     
     
     
297. TADYANEMHANDU C, Garvey C, Chin A, Metcalfe J, et al
     More should be done now for patients with TB-associated chronic lung disease.
     Int J Tuberc Lung Dis. 2019;23:1122-1123.
     PubMed    
     
     
     
298. JINDAL SK
     Searching for a mole in the hill.
     Int J Tuberc Lung Dis. 2019;23:1047.
     PubMed    
     
     
     September 2019
299. VANINO E, Tadolini M, Attard L, Cascavilla A, et al
     A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care.
     Int J Tuberc Lung Dis. 2019;23:1042.
     PubMed    
     
     
     
300. GALEGO MA, Santos JV, Viana J, Freitas A, et al
     To be or not to be hospitalised with tuberculosis in Portugal.
     Int J Tuberc Lung Dis. 2019;23:1029-1034.
     PubMed     Abstract available
     
     
     
301. DI BELLA S, Siroka A, Antonello RM, Zignol M, et al
     Tuberculosis screening in outpatient healthcare workers: lessons from a high-income, low TB burden country.
     Int J Tuberc Lung Dis. 2019;23:1024-1028.
     PubMed     Abstract available
     
     
     
302. HUGHES J, Reuter A, Chabalala B, Isaakidis P, et al
     Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting.
     Int J Tuberc Lung Dis. 2019;23:1017-1023.
     PubMed     Abstract available
     
     
     
303. PEREA-JACOBO R, Muniz-Salazar R, Laniado-Laborin R, Cabello-Pasini A, et al
     Rifampin pharmacokinetics in tuberculosis-diabetes mellitus patients: a pilot study from Baja California, Mexico.
     Int J Tuberc Lung Dis. 2019;23:1012-1016.
     PubMed     Abstract available
     
     
     
304. BUZIASHVILI M, Mirtskhulava V, Kipiani M, Blumberg HM, et al
     Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.
     Int J Tuberc Lung Dis. 2019;23:1005-1011.
     PubMed     Abstract available
     
     
     
305. OTA M, Uchimura K
     Trends of tuberculosis rates before and after the declaration as a public health emergency in Japan, 1992-2006.
     Int J Tuberc Lung Dis. 2019;23:1000-1004.
     PubMed     Abstract available
     
     
     
306. HELD K, McAnaw S, Chiang CY, Trebucq A, et al
     Progress in global rollout of new multidrug-resistant tuberculosis treatments.
     Int J Tuberc Lung Dis. 2019;23:996-999.
     PubMed     Abstract available
     
     
     
307. ZHANG HC, Ruan QL, Wu J, Zhang S, et al
     Serial T-SPOT.TB in household contacts of tuberculosis patients: a 6-year observational study in China.
     Int J Tuberc Lung Dis. 2019;23:989-995.
     PubMed     Abstract available
     
     
     
308. FARLEY JE, McKenzie-White J, Bollinger R, Hong H, et al
     Evaluation of miLINC to shorten time to treatment for rifampicin-resistant Mycobacterium tuberculosis.
     Int J Tuberc Lung Dis. 2019;23:980-988.
     PubMed     Abstract available
     
     
     
309. SMITTIPAT N, Miyahara R, Juthayothin T, Billamas P, et al
     Indo-Oceanic Mycobacterium tuberculosis strains from Thailand associated with higher mortality.
     Int J Tuberc Lung Dis. 2019;23:972-979.
     PubMed     Abstract available
     
     
     
310. MISHRA B, Mohapatra PR
     Expand the RRDR hotspot to improve GeneXpert results.
     Int J Tuberc Lung Dis. 2019;23:1043.
     PubMed    
     
     
     
311. HARRIES AD, Chakaya JM
     Assessing and managing pulmonary impairment in those who have completed TB treatment in programmatic settings.
     Int J Tuberc Lung Dis. 2019;23:1044-1045.
     PubMed    
     
     
     
312. HARRIES AD, Timire C, Takarinda KC, Sandy C, et al
     Ensuring that Xpert((R)) MTB/RIF is used to its maximum potential.
     Int J Tuberc Lung Dis. 2019;23:1043-1044.
     PubMed    
     
     
     July 2019
313. MARTINEZ-GIRON R, van Woerden HC
     The recognition of Lophomonas blattarum in fresh respiratory samples in recent correspondence.
     Int J Tuberc Lung Dis. 2019;23:873-874.
     PubMed    
     
     
     
314. SILVA A, Ponte C, Antas PRZ
     What a difference a strain makes!
     Int J Tuberc Lung Dis. 2019;23:874.
     PubMed    
     
     
     
315. NDAKIDEMI E, Emerson C, Medley A, Ngowi B, et al
     Health care worker perspectives on TB case finding and HIV services among pediatric TB patients in Tanzania.
     Int J Tuberc Lung Dis. 2019;23:811-816.
     PubMed     Abstract available
     
     
     June 2019
316. KAMAT AS, Gretschel A, Vlok AJ, Solomons R, et al
     Reply to "Cerebrospinal fluid protein and shunt obstruction in tuberculous meningitis".
     Int J Tuberc Lung Dis. 2019;23:767-768.
     PubMed    
     
     
     
317. FIGAJI A, Fieggen G, Enslin N, Taylor A, et al
     Cerebrospinal fluid protein and shunt obstruction in tuberculous meningitis.
     Int J Tuberc Lung Dis. 2019;23:765.
     PubMed    
     
     
     
318. ASSEFA Y, Woldeyohannes S, Gelaw YA, Hamada Y, et al
     Screening tools to exclude active pulmonary TB in high TB burden countries: systematic review and meta-analysis.
     Int J Tuberc Lung Dis. 2019;23:728-734.
     PubMed     Abstract available
     
     
     May 2019
319. MITCHELL EMH, Heumann SG, Sprague L, Tesfaye DH, et al
     'Reservoir of infection' or 'fount of knowledge'? Forging equal partnerships and shifting power to address LTBI.
     Int J Tuberc Lung Dis. 2019;23:527-528.
     PubMed    
     
     
     
320. HAROUNA SH, Ortuno-Gutierrez N, Souleymane MB, Kizito W, et al
     Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger.
     Int J Tuberc Lung Dis. 2019;23:625-630.
     PubMed     Abstract available
     
     
     
321. ISMAIL NA, Said HM, Rodrigues C, Omar SV, et al
     Multicentre study to establish interpretive criteria for clofazimine drug susceptibility testing.
     Int J Tuberc Lung Dis. 2019;23:594-599.
     PubMed     Abstract available
     
     
     
322. BERROCAL-ALMANZA LC, Botticello J, Piotrowski H, Karnani N, et al
     Engaging with civil society to improve access to LTBI screening for new migrants in England: a qualitative study.
     Int J Tuberc Lung Dis. 2019;23:563-570.
     PubMed     Abstract available
     
     
     April 2019
323. KYI MS, Aung ST, Oo HN, Chongsuvivatwong V, et al
     Fully vs. partially integrated services for TB-HIV in Myanmar: a health services review and a cohort study.
     Int J Tuberc Lung Dis. 2019;23:498-506.
     PubMed     Abstract available
     
     
     
324. EPSTEIN RL, Bhagavathula M, Saag LA, Verma S, et al
     QuantiFERON((R))-TB Gold In-Tube reliability for immigrants with parasitic infections in Boston, USA.
     Int J Tuberc Lung Dis. 2019;23:482-490.
     PubMed     Abstract available
     
     
     March 2019
325. BERHANU RH, Schnippel K, Kularatne R, Firnhaber C, et al
     Discordant rifampicin susceptibility results are associated with Xpert((R)) MTB/RIF probe B and probe binding delay.
     Int J Tuberc Lung Dis. 2019;23:358-362.
     PubMed     Abstract available
     
     
     
326. LAI J, Dememew Z, Jerene D, Abashawl A, et al
     Provider barriers to the uptake of isoniazid preventive therapy among people living with HIV in Ethiopia.
     Int J Tuberc Lung Dis. 2019;23:371-377.
     PubMed     Abstract available
     
     
     
327. KURTZ T, Feil AC, Nascimento LS, de Oliveira Abreu P, et al
     Effect of neonatal bacille Calmette-Guerin on the tuberculin skin test reaction in the first 2 years of life.
     Int J Tuberc Lung Dis. 2019;23:344-348.
     PubMed     Abstract available
     
     
     
328. KYAW NTT, Kumar AMV, Kyaw KWY, Satyanarayana S, et al
     IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality.
     Int J Tuberc Lung Dis. 2019;23:322-330.
     PubMed     Abstract available
     
     
     February 2019
329. SULEIMAN K, England K, Lessem E, McKenna L, et al
     Key features to consider in revising the Model List of Essential In Vitro Diagnostics: a TB perspective.
     Int J Tuberc Lung Dis. 2019;23:272.
     PubMed    
     
     
     
330. SYKES CA, Shepherd J, McGoldrick C, Kennedy N, et al
     A case of rifampicin-induced haemolysis.
     Int J Tuberc Lung Dis. 2019;23:239-240.
     PubMed     Abstract available
     
     
     
331. VAN AERDE KJ, van der Heijden EHFM, Henriet SS, Merkus PJ, et al
     A case promoting use of ultrasound-guided sampling techniques to correctly diagnose MDR-TB in children.
     Int J Tuberc Lung Dis. 2019;23:236-238.
     PubMed     Abstract available
     
     
     
332. RENDON A, Silva DR, Esposito S, Sotgiu G, et al
     Launching the Global TB Network.
     Int J Tuberc Lung Dis. 2019;23:123-124.
     PubMed    
     
     
     January 2019
333. REIMANN M, Schaub D, Kalsdorf B, Runge C, et al
     Cigarette smoking and culture conversion in patients with susceptible and M/XDR-TB.
     Int J Tuberc Lung Dis. 2019;23:93-98.
     PubMed     Abstract available
     
     
     
334. AGIZEW T, Boyd R, Auld AF, Payton L, et al
     Treatment outcomes, diagnostic and therapeutic impact: Xpert vs. smear. A systematic review and meta-analysis.
     Int J Tuberc Lung Dis. 2019;23:82-92.
     PubMed     Abstract available
     
     
     
335. PEDRAZZOLI D, Borghi J, Viney K, Houben RMGJ, et al
     Measuring the economic burden for TB patients in the End TB Strategy and Universal Health Coverage frameworks.
     Int J Tuberc Lung Dis. 2019;23:5-11.
     PubMed     Abstract available
     
     
     
336. AGGERBECK H, Ruhwald M, Hoff ST, Tingskov PN, et al
     Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial.
     Int J Tuberc Lung Dis. 2019;23:38-44.
     PubMed     Abstract available
     
     
     
337. VAN DEUN A, Tahseen S, Affolabi D, Hossain MA, et al
     Sputum smear microscopy in the Xpert((R)) MTB/RIF era.
     Int J Tuberc Lung Dis. 2019;23:12-18.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: